137 related articles for article (PubMed ID: 1078826)
1. Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.
Levin AS; Byers VS; Fudenberg HH; Wybran J; Hackett AJ; Johnston JO; Spitler LE
J Clin Invest; 1975 Mar; 55(3):487-99. PubMed ID: 1078826
[TBL] [Abstract][Full Text] [Related]
2. Transfer factor therapy in osteogenic sarcoma.
Levin AS; Byers VS; Fudenberg HH; Wybran J; Hackett AJ; Johnston JO
Trans Assoc Am Physicians; 1974; 87():153-8. PubMed ID: 4549141
[No Abstract] [Full Text] [Related]
3. Tumor-specific cell-mediated immunity in household contacts of cancer patients.
Byers VS; Levin AS; Hackett AJ; Fudenberg HH
J Clin Invest; 1975 Mar; 55(3):500-13. PubMed ID: 1078827
[TBL] [Abstract][Full Text] [Related]
4. Disapperance of osteogenic sarcoma after irradiation: immunologic observations.
Urtasun RC; Connachie PR
J Can Assoc Radiol; 1976 Jun; 27(2):80-3. PubMed ID: 1066352
[TBL] [Abstract][Full Text] [Related]
5. Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma.
Yu A; Watts H; Jaffe N; Parkman R
N Engl J Med; 1977 Jul; 297(3):121-7. PubMed ID: 325412
[TBL] [Abstract][Full Text] [Related]
6. Levels of cytotoxic reactivity to cultured normal skin fibroblasts in sera from normal and sarcoma-bearing patients.
Catapano MS; Brown JM; Rosenberg SA
Cancer Res; 1980 Apr; 40(4):979-83. PubMed ID: 6928402
[TBL] [Abstract][Full Text] [Related]
7. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
8. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
9. Surgical treatment of bone tumors in conjunction with microwave-induced hyperthermia and adjuvant immunotherapy. A preliminary report.
Fan Q; Ma B; Guo A; Li Y; Ye J; Zhou Y; Qiu X
Chin Med J (Engl); 1996 Jun; 109(6):425-31. PubMed ID: 9206073
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy.
Sears HF; Simon R; Rosenberg SA
Cancer Treat Rep; 1980; 64(4-5):589-97. PubMed ID: 6933004
[TBL] [Abstract][Full Text] [Related]
11. Rosette-forming cells, immunologic deficiency diseases and transfer factor.
Wybran J; Levin AS; Spitler LE; Fudenberg HH
N Engl J Med; 1973 Apr; 288(14):710-3. PubMed ID: 4540063
[No Abstract] [Full Text] [Related]
12. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma.
Tsuji H; Kawaguchi S; Wada T; Nagoya S; Inobe M; Yamashita T; Ishii S; Uede T
Cancer Gene Ther; 2002 Sep; 9(9):747-55. PubMed ID: 12189524
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunity in human osteogenic sarcoma.
Gangal SG; Agashe SS; Nair PN; Rao RS
Indian J Cancer; 1973 Sep; 10(3):295-301. PubMed ID: 4522531
[No Abstract] [Full Text] [Related]
15. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
16. Effect of radiotherapy on lymphocyte cytotoxicity in vitro.
Wasserman J; Melén B; Blomgren H; Glas U; Perlmann P
Clin Exp Immunol; 1975 Nov; 22(2):230-9. PubMed ID: 1082400
[TBL] [Abstract][Full Text] [Related]
17. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
18. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
19. Cell mediated immunity in human osteogenic sarcoma.
Agashe SS; Nair PN; Rao RS; Gangal SG
Indian J Cancer; 1975 Mar; 12(1):61-6. PubMed ID: 1058832
[No Abstract] [Full Text] [Related]
20. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
